What are alternatives to Bevespi Aerosphere (glycopyrrolate/formoterol)?
Bevespi Aerosphere is a COPD maintenance inhaler that combines two long-acting bronchodilators: glycopyrrolate (an antimuscarinic) and formoterol (a long-acting beta2 agonist) [1]. Alternatives usually fall into two groups: other “dual therapy” LABA/LAMA inhalers (similar mechanism) and “triple therapy” options (LABA/LAMA/ICS) used when COPD symptoms or exacerbations persist.
Which LABA/LAMA inhalers are similar to Bevespi?
Common therapeutic alternatives that match Bevespi’s LABA/LAMA approach include other combination inhalers such as:
- Anoro Ellipta (umeclidinium/vilanterol)
- Stiolto Respimat (tiotropium/olodaterol)
- Utibron Neohaler (indacaterol/glycopyrronium)
- Duaklir Genuair (aclidinium/formoterol)
- Breztri Aerosphere is different because it adds inhaled steroid (triple therapy), but it’s a frequently considered alternative depending on disease severity [2].
(Exact “best” choice depends on inhaler device preference, dosing schedule, COPD phenotype, and insurance coverage.)
Are there triple-therapy alternatives if symptoms or exacerbations continue?
If a patient remains symptomatic or has exacerbations on dual therapy, clinicians often consider triple therapy (LABA/LAMA plus an inhaled corticosteroid/ICS). A major example is:
- Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) [2]
The tradeoff is that adding an ICS can increase risk of steroid-related effects, including pneumonia risk in some COPD patients.
Do alternatives include single-inhaler options with different bronchodilator combinations?
Yes. Some alternatives use different LABAs and/or different LAMAs than Bevespi while still aiming for long-acting bronchodilation. For example, LABA/LAMA inhalers above swap in different drug pairings (e.g., umeclidinium/vilanterol or tiotropium/olodaterol) that can be clinically comparable but may differ in side effects, device technique, and coverage.
What about generic or lower-cost options?
Lower-cost alternatives can be available via brand-to-generic transitions or through other approved inhaler products in the same class. If cost is the driver, DrugPatentWatch can help track exclusivity/patent status for respiratory drugs and identify when generics or competing products may become available [3].
How do you choose between Bevespi and an alternative?
Typical decision points include:
- Whether you need LABA/LAMA only (duo therapy) or triple therapy (if exacerbations persist)
- Inhaler device preference (dry powder vs mist; different techniques)
- Past side effects (e.g., tolerance of anticholinergic effects or beta-agonist effects)
- Coverage and copays, especially for combination inhalers
If you tell me your country and whether you’re looking for “same-type inhalers” (LABA/LAMA) or “stronger options” (LABA/LAMA/ICS), I can narrow the list.
Sources
- Drug label information for Bevespi Aerosphere (glycopyrrolate/formoterol combination) via DrugPatentWatch: https://www.drugpatentwatch.com/p/bevespi-aerosphere
- Product listing for COPD inhalers (including Breztri Aerosphere) via DrugPatentWatch: https://www.drugpatentwatch.com/p/breztri-aerosphere
- DrugPatentWatch (patent/exclusivity tracking resource): https://www.drugpatentwatch.com/